Eloxx Pharmaceuticals, Inc. (ELOX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | -5.82 Million USD | 79.79% |
| 2021 | -28.81 Million USD | -128.1% |
| 2020 | -12.63 Million USD | -87.65% |
| 2019 | -6.73 Million USD | 86.15% |
| 2018 | -48.6 Million USD | -102.11% |
| 2017 | -24.04 Million USD | -6531.52% |
| 2016 | 373.92 Thousand USD | 146.12% |
| 2015 | -810.8 Thousand USD | 75.69% |
| 2014 | -3.33 Million USD | 45.44% |
| 2013 | -6.11 Million USD | -1145.05% |
| 2012 | 584.78 Thousand USD | 195.67% |
| 2011 | 197.78 Thousand USD | 114.02% |
| 2010 | -1.41 Million USD | 75.81% |
| 2009 | -5.83 Million USD | -1457.75% |
| 2008 | -374.35 Thousand USD | 93.41% |
| 2007 | -5.67 Million USD | -1291.2% |
| 2006 | -408.06 Thousand USD | -28.13% |
| 2005 | -318.47 Thousand USD | -9.12% |
| 2004 | -291.85 Thousand USD | -56.7% |
| 2003 | -186.24 Thousand USD | 41.78% |
| 2002 | -319.93 Thousand USD | 59.94% |
| 2001 | -798.71 Thousand USD | -5473.7% |
| 2000 | -14.33 Thousand USD | 99.08% |
| 1999 | -1.55 Million USD | -64.34% |
| 1998 | -946.69 Thousand USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 1.77 Million USD | 33.26% |
| 2023 Q1 | 1.33 Million USD | 122.87% |
| 2023 Q3 | 983 Thousand USD | -44.62% |
| 2022 Q2 | -16.61 Million USD | 36.99% |
| 2022 FY | -5.82 Million USD | 79.79% |
| 2022 Q4 | -5.82 Million USD | 47.75% |
| 2022 Q1 | -26.36 Million USD | 8.5% |
| 2022 Q3 | -11.14 Million USD | 32.91% |
| 2021 Q4 | -28.81 Million USD | 25.92% |
| 2021 Q1 | -7.48 Million USD | 40.76% |
| 2021 FY | -28.81 Million USD | -128.1% |
| 2021 Q2 | -45.53 Million USD | -508.63% |
| 2021 Q3 | -38.89 Million USD | 14.6% |
| 2020 Q4 | -12.63 Million USD | 26.99% |
| 2020 FY | -12.63 Million USD | -87.65% |
| 2020 Q1 | -10.89 Million USD | -61.88% |
| 2020 Q3 | -17.3 Million USD | -9.39% |
| 2020 Q2 | -15.81 Million USD | -45.15% |
| 2019 Q1 | -29.07 Million USD | 40.18% |
| 2019 FY | -6.73 Million USD | 86.15% |
| 2019 Q2 | -33.8 Million USD | -16.24% |
| 2019 Q3 | -6.6 Million USD | 80.46% |
| 2019 Q4 | -6.73 Million USD | -1.92% |
| 2018 Q1 | -18.29 Million USD | 0.0% |
| 2018 Q4 | -48.6 Million USD | 12.16% |
| 2018 Q2 | -63.41 Million USD | -246.7% |
| 2018 FY | -48.6 Million USD | -102.11% |
| 2018 Q3 | -55.33 Million USD | 12.74% |
| 2017 FY | -24.04 Million USD | -6531.52% |
| 2017 Q2 | 373.92 Thousand USD | 2414.79% |
| 2017 Q1 | 14.86 Thousand USD | -90.14% |
| 2017 Q3 | -245.53 Thousand USD | -165.67% |
| 2016 Q2 | -810.8 Thousand USD | 46.85% |
| 2016 FY | 373.92 Thousand USD | 146.12% |
| 2016 Q1 | -1.52 Million USD | 35.54% |
| 2016 Q3 | -287.06 Thousand USD | 64.6% |
| 2016 Q4 | 150.8 Thousand USD | 152.53% |
| 2015 Q3 | -3.35 Million USD | -0.61% |
| 2015 Q1 | -469.98 Thousand USD | 77.7% |
| 2015 Q4 | -2.36 Million USD | 29.46% |
| 2015 FY | -810.8 Thousand USD | 75.69% |
| 2015 Q2 | -3.33 Million USD | -609.53% |
| 2014 Q2 | -6.11 Million USD | 1.4% |
| 2014 Q3 | -3.83 Million USD | 37.21% |
| 2014 Q4 | -2.1 Million USD | 45.08% |
| 2014 FY | -3.33 Million USD | 45.44% |
| 2014 Q1 | -6.19 Million USD | -57.52% |
| 2013 Q2 | 584.78 Thousand USD | -3.51% |
| 2013 Q4 | -3.93 Million USD | -381.48% |
| 2013 FY | -6.11 Million USD | -1145.05% |
| 2013 Q1 | 606.04 Thousand USD | -61.13% |
| 2013 Q3 | 1.39 Million USD | 139.04% |
| 2012 Q4 | 1.55 Million USD | 75.75% |
| 2012 FY | 584.78 Thousand USD | 195.67% |
| 2012 Q1 | -1 Million USD | -256.01% |
| 2012 Q2 | 197.78 Thousand USD | 119.62% |
| 2012 Q3 | 887.05 Thousand USD | 348.5% |
| 2011 Q3 | -642.86 Thousand USD | 54.43% |
| 2011 Q1 | -2.66 Million USD | -0.89% |
| 2011 Q4 | 646.21 Thousand USD | 200.52% |
| 2011 Q2 | -1.41 Million USD | 47.08% |
| 2011 FY | 197.78 Thousand USD | 114.02% |
| 2010 FY | -1.41 Million USD | 75.81% |
| 2010 Q1 | 2.34 Million USD | 490.49% |
| 2010 Q3 | -3.99 Million USD | 31.47% |
| 2010 Q2 | -5.83 Million USD | -349.14% |
| 2010 Q4 | -2.64 Million USD | 33.88% |
| 2009 Q3 | -157.38 Thousand USD | 57.96% |
| 2009 Q1 | -276.53 Thousand USD | 72.77% |
| 2009 Q4 | -599.42 Thousand USD | -280.86% |
| 2009 FY | -5.83 Million USD | -1457.75% |
| 2009 Q2 | -374.35 Thousand USD | -35.37% |
| 2008 Q2 | -5.67 Million USD | -75.77% |
| 2008 FY | -374.35 Thousand USD | 93.41% |
| 2008 Q1 | -3.22 Million USD | 33.79% |
| 2008 Q4 | -1.01 Million USD | 58.67% |
| 2008 Q3 | -2.45 Million USD | 56.72% |
| 2007 Q2 | -408.06 Thousand USD | 12.11% |
| 2007 FY | -5.67 Million USD | -1291.2% |
| 2007 Q3 | -1.62 Million USD | -299.03% |
| 2007 Q4 | -4.87 Million USD | -199.59% |
| 2007 Q1 | -464.28 Thousand USD | -22.31% |
| 2006 Q1 | -442.51 Thousand USD | -454.45% |
| 2006 FY | -408.06 Thousand USD | -28.13% |
| 2006 Q3 | -355.38 Thousand USD | -11.59% |
| 2006 Q2 | -318.47 Thousand USD | 28.03% |
| 2006 Q4 | -379.58 Thousand USD | -6.81% |
| 2005 FY | -318.47 Thousand USD | -9.12% |
| 2005 Q3 | -584.28 Thousand USD | -100.19% |
| 2005 Q2 | -291.85 Thousand USD | -49.71% |
| 2005 Q1 | -194.95 Thousand USD | 69.51% |
| 2005 Q4 | -79.81 Thousand USD | 86.34% |
| 2004 Q1 | -3.75 Million USD | -1236.9% |
| 2004 Q2 | -186.24 Thousand USD | 95.04% |
| 2004 FY | -291.85 Thousand USD | -56.7% |
| 2004 Q3 | -119.29 Thousand USD | 35.95% |
| 2004 Q4 | -639.49 Thousand USD | -436.06% |
| 2003 Q2 | -319.93 Thousand USD | -319.64% |
| 2003 Q1 | -76.23 Thousand USD | 82.55% |
| 2003 Q4 | -280.96 Thousand USD | -0.87% |
| 2003 FY | -186.24 Thousand USD | 41.78% |
| 2003 Q3 | -278.53 Thousand USD | 12.94% |
| 2002 Q4 | -436.78 Thousand USD | -24.0% |
| 2002 FY | -319.93 Thousand USD | 59.94% |
| 2002 Q1 | -3.48 Million USD | -23.81% |
| 2002 Q2 | -798.71 Thousand USD | 77.09% |
| 2002 Q3 | -352.24 Thousand USD | 55.9% |
| 2001 Q3 | 361.84 Thousand USD | 2625.07% |
| 2001 Q1 | -323.75 Thousand USD | 47.79% |
| 2001 FY | -798.71 Thousand USD | -5473.7% |
| 2001 Q2 | -14.33 Thousand USD | 95.57% |
| 2001 Q4 | -2.81 Million USD | -878.36% |
| 2000 Q3 | -1.12 Million USD | 27.54% |
| 2000 FY | -14.33 Thousand USD | 99.08% |
| 2000 Q1 | -140.63 Thousand USD | -40.63% |
| 2000 Q2 | -1.55 Million USD | -1006.26% |
| 2000 Q4 | -620.12 Thousand USD | 44.99% |
| 1999 Q4 | -100 Thousand USD | 0.0% |
| 1999 FY | -1.55 Million USD | -64.34% |
| 1998 FY | -946.69 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 420.628% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -52.634% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 564.354% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 118.075% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -520.128% |
| Better Therapeutics, Inc. | -860 Thousand USD | -577.093% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 75.518% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 1872.921% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 227.418% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 282.083% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 283.883% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 216.413% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 104.344% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 3350.349% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 147.194% |
| Molecular Templates, Inc. | 707 Thousand USD | 923.621% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 1428.106% |
| NexImmune, Inc. | -3.13 Million USD | -85.822% |
| Orgenesis Inc. | 21.78 Million USD | 126.731% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 322.592% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -1169177.108% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -23.614% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -4574.293% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 105.252% |
| Statera Biopharma, Inc. | 14.41 Million USD | 140.391% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 23.341% |
| Trevena, Inc. | 2.25 Million USD | 357.883% |
| Vaxxinity, Inc. | 10.13 Million USD | 157.471% |
| Vaccinex, Inc. | -1.28 Million USD | -352.096% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 1790.541% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 143.984% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 8191.771% |